Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2009 Results
Date:8/10/2009

nificant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's products to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements for its products; a lack of acceptance of Vanda's products in the marketplace, or a failure to become or remain profitable; Vanda's expectations regarding trends with respect to its costs and expenses; Vanda's inability to obtain the capital necessary to fund its commercial and research and development activities; Vanda's failure to identify or obtain rights to new products; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2009 (File No. 001-34186). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf a
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports First Quarter 2009 Results
9. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
10. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 Research and Markets has ... Proteomics Analytical Instruments Market 2014-2018" report to their ... Genomics is the study of the gene and ... structure and functions of proteomes or sets of proteins ... Genomics involves the mapping of genes and DNA sequencing ...
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 ... seven-year contract with the National Institute of Allergy and ... Health, to conduct preclinical development of potential therapies for ... of drugs to treat HIV and AIDS and the ... well as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... to be semi-finalists in Livestrong’s Big C Competition. Out ... Health are each headed to the semi-final round. In ... Livestrong’s exclusive three-month accelerator program, complete with mentoring from ... , As part of the angelMD commitment to ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... Brad Thompson, President,and CEO of Oncolytics Biotech Inc. (TSX: ... Company at the Maxim Group Growth Conference at,2:30 p.m. ... being held at the,Grand Hyatt Hotel in New York., ... is available at, http://www.wsw.com/webcast/maxim/oncy/ on the company,s website ...
... Engineering and Operations Appointed -, CLINTON, N.J., ... appointment of Michael Kennedy as Senior Vice President,Engineering ... responsible for,drug-device technology strategy and development., "Michael,s ... critical care as we continue to advance our ...
... Oct. 2 ,ImpediMed Ltd, a pioneer in ... Inc., a global leader in science-based,nutraceutical products, ... announced an agreement to distribute ImpediMed technology,in ... affiliate, Health,World, Ltd, has been a long-standing ...
Cached Biology Technology:Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference 2Ikaria Strengthens Executive Leadership Team 2ImpediMed and Metagenics Announce Agreement 2
(Date:7/24/2014)... TORONTO, June 24, 2014 Some sticky research out ... fight against a certain species of toxic grass fungus: ... this month,s Biology Letters , "Ungulate saliva inhibits ... when applied to red fescue grass (which hosts a ... results in slower fungus growth and less toxicity. , ...
(Date:7/24/2014)... Iyer, O.D., a low vision specialist at The University ... School, has been awarded a grant to help Harris ... eyeglasses, medication or surgery. , Even with corrective lenses, ... best. However, there are a variety of low vision ... help offset their vision loss. , Iyer is using ...
(Date:7/24/2014)... fire hazard in the United States, wildland managers often ... and suppressed trees (ladder fuels). These cuttings and ... low fire danger in order to dispose of the ... pollutants, managers often cover all or part of the ... as agricultural plastic, in order to keep water out. ...
Breaking Biology News(10 mins):Moose drool inhibits growth of toxic fungus: York U research 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... and a half acres of Appalachia have been strip-mined, whole ... and communities devastated. Not exactly a promising place for a ... For his startling and bold proposal to clean-up this ... of Appalachia, John Todd, a research professor in the Rubenstein ...
... drug reverses the brain dysfunction inflicted by a genetic ... of TSC patients also suffer from autism, the findings ... autism. Nature Medicine publishes the findings ... mouse model for TSC, the scientists tested rapamycin, a ...
... the Smithsonian,s National Zoo detected a secondary rise in ... Mei Xiang (may-SHONG) earlier this month. The results from ... believe the hormone rise indicates that it would be ... to a cub or comes to the end of ...
Cached Biology News:Buckminster Fuller takes on big coal 2Buckminster Fuller takes on big coal 3Drug reverses mental retardation caused by genetic disorder 2
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
Biology Products: